PUBLISHER: TechNavio | PRODUCT CODE: 1125054
PUBLISHER: TechNavio | PRODUCT CODE: 1125054
Technavio has been monitoring the viral vectors market and it is poised to grow by $ 490.64 mn during 2022-2026, accelerating at a CAGR of 14.23% during the forecast period. Our report on the viral vectors market provides a holistic analysis, market size and forecast, trends, growth drivers, challenges, and vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of chronic diseases, increasing use of viral vectors to develop gene therapies and vaccines and growing funding for and investments in gene therapies and vaccines.
The viral vectors market analysis includes the application segment and geographic landscape.
Technavio's viral vectors market is segmented as below:
By Application
By Geographical Landscape
This study identifies the increasing number of R&D activities for the development of gene therapies and vaccines using viral vectors as one of the prime reasons driving the viral vector market growth during the next few years. Also, the rising number of M&A and collaborations and the emergence of novel technologies to manufacture viral vectors will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the viral vectors market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading viral vectors market vendors that include Batavia Biosciences BV, Bayer AG, Catalent Inc., Creative Biogene, Danaher Corp., F. Hoffmann La Roche Ltd., FinVector Oy, Freeline Therapeutics Holdings plc, FUJIFILM Holdings Corp, Institut Merieux, Lonza Group Ltd., Merck KGaA, Novartis AG, Oxford Biomedica Plc, REGENXBIO Inc, Sirion Biotech GmbH, Takara Holdings Inc, Thermo Fisher Scientific Inc., uniQure NV, and Virovek Inc. Also, the viral vectors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: